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SUMMARY 66 
 67 
Respiratory syncytial virus (RSV) is an important aetiological agent of respiratory infections, 68 
particularly in children. Much data regarding the immune response to RSV comes from 69 
animal models and in vitro studies. Here, we provide a comprehensive description of the 70 
human immune response to RSV infection, based on a systematic literature review of 71 
research in infected humans. 72 
 73 
There is an initial strong neutrophil response to RSV infection in humans, positively 74 
correlated with disease severity and mediated by IL-8. Dendritic cells migrate to the lungs as 75 
the primary antigen presenting cell. An initial systemic T-cell lymphopenia is followed by a 76 
pulmonary CD8+ T-cell response, mediating viral clearance. Humoral immunity to re-77 
infection is incomplete but RSV-IgG and -IgA are protective. B-cell stimulating factors 78 
derived from airway epithelium play a major role in protective antibody generation. IFN-γ 79 
has a strongly protective role and a Th2-biased response may be deleterious. Other cytokines 80 
(particularly IL-17A), chemokines (particularly CCL-5 and CCL-3) and local innate immune 81 
factors (including cathelicidins and IFN-λ) contribute to pathogenesis. 82 
 83 
In summary, neutrophilic inflammation is incriminated as a harmful response whereas CD8+ 84 
T-cells and IFN-γ have protective roles. These may represent important therapeutic targets to 85 
modulate the immunopathogenesis of RSV infection. 86 
87 
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INTRODUCTION 88 
 89 
Respiratory syncytial virus (RSV) is an enveloped single-stranded RNA virus belonging to 90 
the Pneumoviridae family of the Mononegavirales order. Infections occur worldwide, with 91 
outbreaks in temperate climates occurring primarily during the winter months. RSV is an 92 
important aetiological agent of respiratory infections, particularly in children, causing a 93 
spectrum of illness encompassing upper respiratory tract infections (URTI) and lower 94 
respiratory tract infections (LRTI), including pneumonia and bronchiolitis which are 95 
associated with greater morbidity and mortality. Natural infection results in incomplete 96 
immunity, permitting recurrent infection in childhood as well as infections in adults and the 97 
elderly. Much data regarding the immune response to RSV comes from murine and other 98 
animal models and in vitro human cell culture studies. While important for hypothesis 99 
generation, these methodologies may not provide a completely accurate reflection of the 100 
immune response during infection in humans. Here, we provide a comprehensive description 101 
of the human immune response to RSV infection, based on a systematic literature review 102 
exclusively of clinical, ex vivo and post mortem data from naturally and experimentally 103 
infected humans. 104 
 105 
In this review we consider the existing data describing the major cellular and humoral 106 
components of the immune response to RSV, distinguishing events occurring systemically 107 
from those occurring locally within the respiratory tract. First we describe the behaviour of 108 
all major immune cell types, encompassing neutrophils, dendritic cells, monocytes, 109 
macrophages, eosinophils and T-lymphocytes. Secondly, the anti-RSV antibody response and 110 
its regulation is discussed. Next, the distinct Th1 and Th2 responses to RSV and the effect of 111 
their balance on disease progression are considered. Several chemokines, cytokines and other 112 
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immune molecules have been demonstrated to be involved in the immune response and are 113 
reviewed. The global host transcriptional response is also discussed in the context of 114 
immune-related pathways. Certain key pathogen-host interactions described herein may 115 
represent targets for the development of novel therapeutics. For completeness, we summarise 116 
the association between RSV infection and subsequent asthma and also key differences 117 
between immune responses in humans and animals used in model systems of infection.  118 
 119 
METHODS OF SYSTEMATIC LITERATURE REVIEW 120 
 121 
We conducted a systematic literature review following PRISMA (Preferred Reporting Items 122 
for Systematic Reviews and Meta-Analyses) guidelines (PROSPERO registration number 123 
CRD42016047320). An electronic literature search of Medline, Embase and Web of Science 124 
was performed using the following search terms: ((RSV[Title] OR respiratory syncytial 125 
virus[Title])) AND (Immune response OR T-cell OR B-cell OR lymphocyte OR macrophage 126 
OR neutrophil OR monocyte OR natural killer cell OR dendritic cell OR immunoglobulin 127 
OR IgG OR IgA OR IgE OR cytokine OR chemokine OR interleukin OR interferon) AND 128 
(Human OR clinical OR experimental OR neonate OR infant OR children OR adult OR 129 
elderly)). 130 
 131 
The last search was conducted on 16th May 2016. The results from the databases were 132 
merged and duplicates removed. The combined results of the electronic database search were 133 
assessed independently by two authors and discrepancies discussed and agreed upon 134 
according to the inclusion and exclusion criteria. Publications in all languages describing 135 
primary research in humans were included (clinical, ex vivo, post mortem). Editorials, 136 
reviews, commentaries and opinion pieces were excluded. Articles were limited to those 137 
  7 
published after 1990. Additional articles of interest were identified from reviewing the 138 
bibliographies of relevant articles. The literature search resulted in 2541 publications after 139 
removal of duplicates and pre-1990 publications. Two authors reviewed titles and abstracts 140 
and identified 268 records that then underwent full text review. Of these, 166 met the 141 
inclusion criteria. A further 9 articles were identified through other sources including 142 
bibliographies of identified articles. 143 
 144 
SYSTEMIC AND PULMONARY IMMUNE CELL RESPONSES TO RSV 145 
INFECTION 146 
 147 
Neutrophils 148 
 149 
RSV infection elicits a strong systemic and especially respiratory tract neutrophil response 150 
(1-4). Neutrophils are the predominant cell type in bronchoalveolar lavage (BAL) from the 151 
lungs of ventilated infants with severe RSV-bronchiolitis and those with milder infection (5). 152 
These cells are activated during the initial pathogenesis of RSV-LRTI, producing neutrophil 153 
elastase (6, 7) and expressing activation markers (CD11b, CD18 and CD54 [ICAM-1]) (8, 9). 154 
The peak neutrophil response coincides with maximum clinical severity and viral load, and 155 
by the time infants with severe infection are discharged from the intensive care unit (ICU) 156 
after ventilation, neutrophil counts in peripheral blood have normalised (10). Widespread 157 
neutrophil infiltration is seen in lung tissue from fatal cases of RSV-LRTI (3, 11).  158 
 159 
During severe infection the virus interacts directly with neutrophils. Cells from peripheral 160 
blood and BAL express RSV proteins F, G, and N proportionately, implying stoichiometric 161 
expression thus intact intracellular virions (12). RSV genomic RNA and mRNA is also 162 
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present intracellularly (12, 13). This could be explained by phagocytosis of virions or 163 
replication of RSV within neutrophils. These RSV-containing neutrophils detected in the 164 
peripheral blood may have transmigrated from the lungs into the circulation. 165 
 166 
Neutrophil apoptosis and neutrophil extracellular trap formation (‘NETosis’; a unique form 167 
of neutrophil cell death) are active during infection. Proteins involved in apoptosis (Annexin 168 
V and the Fas death receptor CD95) are up-regulated in nasopharyngeal fluid and NETs are 169 
present in BAL from ventilated children (8, 14). NETs may prevent spread of infectious 170 
virions and comprise a web-like DNA backbone studded with histones and 171 
cytotoxic/antimicrobial proteins.  172 
 173 
Natural Killer (NK) cells 174 
 175 
RSV infection results in reduced total systemic NK cell counts albeit with an increase in an 176 
activated sub-set that lacks expression of CD94 (15, 16). Circulating NK cells have higher 177 
expression of the inhibitory leukocyte immunoglobulin-like receptor subfamily B member 178 
(LILRB1) suggesting they may contribute to regulation of inflammation during infection 179 
(17). Lower systemic total counts correlate with greater severity of infection and NK cells are 180 
sparse in lung tissue from fatal cases (3, 15, 18, 19). In contrast, there is accumulation of 181 
granzyme B-expressing NK cells in the respiratory tract of infants ventilated due to severe 182 
RSV-bronchiolitis (BAL and tracheal aspirate), possibly suggesting migration to the lungs 183 
(20, 21). 184 
 185 
Dendritic Cells (DC) 186 
 187 
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Conventional (cDC) and plasmacytoid (pDC) DCs are mobilized from the circulation to the 188 
nasal mucosa early during infection with a further increase in DC counts during subsequent 189 
convalescence (22, 23). The RSV fusion protein is present within HLA-DR+ DCs in the nasal 190 
mucosa and the selective emigration of DCs, but not monocytes, highlights their likely role as 191 
the primary antigen presenting cell during RSV infection (23). Low numbers of blood pDCS 192 
have been associated with the development of RSV-bronchiolitis suggesting either increased 193 
emigration to the respiratory tract or an insufficient pDC response in severe RSV infection 194 
(24). 195 
 196 
cDCs and pDCs have also been found in the lower airways of infants ventilated due to severe 197 
RSV-bronchiolitis where cDCs exhibit an activated pro-inflammatory phenotype (20). 198 
Circulating cDCs express the activation marker CD83 and the co-stimulatory molecule 199 
CD40. Concentrations of innate immune pro-inflammatory cytokines (IL-6, TNF-α, IL-8) 200 
and T-cell derived cytokines (IFN-γ, IL-13, IL-10, IL-2) in BAL correlate with cDC counts. 201 
In subsets of infants with severe RSV-bronchiolitis (pre-term infants and infants aged four 202 
months or more) pulmonary pDC counts are low compared to term born and younger infants, 203 
suggesting an inadequate antiviral response as a factor in severe RSV disease (20).  204 
 205 
Macrophages and Monocytes 206 
 207 
Alveolar macrophages obtained from BAL from RSV-infected infants and adult transplant 208 
recipients co-express RSV surface glycoproteins, HLA-DR molecules, IL-1β and 209 
cytoplasmic TNF-α, suggesting a local immune-regulatory and antigen presenting role (25, 210 
26). The cells appear to be infected productively, as viral replication from the cells can be 211 
confirmed ex vivo (25).  212 
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 213 
CD69+ monocytes are present in lung tissue from fatal cases of RSV infection (11). In the 214 
peripheral blood, monocytes display reduced TLR8 expression and TNF-α production during 215 
acute RSV-infection, which subsequently normalises in convalescence (27). In contrast, 216 
circulating monocytes increase their expression of TLR4 in RSV infection (28). 217 
Eosinophils 218 
 219 
Eosinophils are activated during the acute phase of RSV-LRTI and may contribute to 220 
recovery. Expression of the myeloid activation marker CD11b on circulating eosinophils 221 
from infants with RSV-LRTI is increased, and inversely correlates with the required duration 222 
of supplemental oxygen (29). In comparison to children hospitalised due to influenza virus or 223 
adenovirus infection, those with RSV infection have higher systemic eosinophil counts 224 
during recovery but not at presentation (30). Despite a lack of data demonstrating significant 225 
eosinophil recruitment to the respiratory tract, there is evidence of eosinophil activity during 226 
bronchiolitis. Leukotriene C4, eosinophil-derived neurotoxin (EDN) and eosinophil cationic 227 
protein (ECP) are elevated in the respiratory tract in RSV-bronchiolitis, detectable in nasal 228 
fluid (leukotriene C4 and ECP) and lower airway secretions (EDN and ECP) (31-33), while 229 
one study did not find increased ECP levels (34). Nasopharyngeal ECP concentrations are 230 
also elevated in children with RSV-LRTI (not specifically bronchiolitis) and URTI (35-39). 231 
Nasal ECP concentrations correlate with nasal concentrations of the neutrophil 232 
chemoattractant CCL-3 (MIP-1α) and systemic neutrophil and eosinophil counts (37, 39). 233 
Concentrations of CCL-5 (RANTES), an eosinophil chemoattractant, ECP and eotaxin all 234 
increase during the progression from acute illness to recovery in RSV-LRTI and correlate 235 
with respiratory tract eosinophil counts suggesting this response may have a role in resolution 236 
(30, 38, 40, 41). In contrast to the apparent pro-resolution role of eosinophils themselves 237 
  11 
during RSV infection it seems that a Th2-biased response, of which eosinophilia is a 238 
component, may be associated with more severe disease and this is discussed in detail in the 239 
section on Th2 responses below. 240 
 241 
T-lymphocytes 242 
 243 
An initial transient systemic T-cell lymphopenia occurs during RSV-LRTI. Counts of CD8+, 244 
CD4+, CD3+ and γδ-T-cells are all reduced, compared to convalescence and non-infected 245 
infants (2, 15, 16, 18, 19, 30, 42-44). There is no increased expression of CD11a (LFA-1α) in 246 
circulating T-cells suggesting that these cells are not activated, nor is there increased 247 
expression of CTLA-4, a marker of down-regulated T-cell activation (45, 46). Absolute T-248 
cell counts during RSV-infection are inversely associated with age, thus T-cell lymphopenia 249 
is more pronounced in younger patients (42). Children with more severe illness and those 250 
requiring ventilation have reduced circulating T-cell counts (all sub-sets) compared to those 251 
with less severe infection and in lung tissue from fatal cases CD4+ and CD8+ T-cells are 252 
sparse (3, 16, 43, 47, 48). During the course of disease, circulating CD8+ T-cell counts 253 
increase (16, 49). In mechanically ventilated infants with severe RSV-LRTI, systemic 254 
effector CD8+ T-cell counts are low during maximum symptoms and viral load and then 255 
peak during convalescence (after the systemic neutrophil response) (10, 49). At the time of 256 
ICU discharge, circulating CD8+ T-cell counts are temporarily elevated, whereas neutrophils 257 
are normal. 258 
 259 
Circulating FOXP3 mRNA and counts of FOXP3+ CD4+ regulatory T-cells (comprising 260 
suppressive resting Treg cells [CD45RA+ FOXP3lo] and suppressive activated Treg cells 261 
[CD45RA+ FOXP3hi]) are reduced in infants hospitalized with RSV-bronchiolitis and for at 262 
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least 3 weeks following acute infection (50, 51). Whether this represents apoptosis or 263 
recruitment to the lungs is unknown. Absolute counts of circulating regulatory T-cells do not 264 
correlate with disease severity (52).  265 
 266 
CD4+ and CD8+ T-cells are present in BAL obtained from infants with RSV-LRTI, with a 267 
predominance of CD4+ T-cells (4, 5). During the course of infection, the expansion of CD8+ 268 
T-cells is greater than that of CD4+ T-cells, and the CD8+ T-cells exhibit an effector 269 
phenotype (HLA-DR+, granzyme-B+, CD38+). Lower respiratory tract (tracheal aspirate and 270 
BAL) granzyme A and B levels are elevated in ventilated patients and granzyme B is 271 
expressed by CD8+ T-cells (21). In bronchiolitis specifically, peripheral blood RSV-specific 272 
cell-mediated cytotoxic immune responses are more frequent in infants with mild compared 273 
to severe infection (53). In experimental RSV infection of adults, the arrival of CD8+ T-cells 274 
to the lungs (in BAL) is associated with a reduction in pulmonary viral load (54). The 275 
frequency of pre-existing RSV-specific pulmonary CD8+ T-cells in BAL is inversely 276 
associated with pulmonary viral load and symptom severity. 277 
 278 
During acute infection, there is up-regulation of Fas and TRAIL receptor expression on 279 
circulating CD4+ and CD8+ T-cells compared to convalescence (42). Systemic 280 
concentrations of soluble Fas ligand and caspase-1 are elevated. An inverse correlation exists 281 
between CD4+ T-cell Fas expression and cell counts. Therefore, one mechanism underlying 282 
systemic lymphopenia may be the induction of T-cell apoptosis as a viral immune evasion 283 
strategy (Figure 1a). Furthermore, programmed cell death 1 (PD-1) protein expression is 284 
specifically up-regulated on pulmonary CD8+ T-cells during RSV-LRTI (55). PD-1 is a T-285 
cell co-inhibitory receptor that is inhibitory to activated T-cells, therefore PD-1 upregulation 286 
could be another immune evasion strategy to blunt the cytotoxic T-cell response (Figure 1b). 287 
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RSV infection may also impair differentiation of CD8+ T-cells into memory cells by 288 
inducing mammalian target of rapamycin (mTOR) activation (Figure 1c) (56). mTOR mRNA 289 
expression is increased in the lungs of infants with RSV-bronchiolitis compared to human 290 
metapneumovirus and rhinovirus infection (and healthy controls) and the RSV cases have a 291 
higher proportion of CD8+mTORser2448+ T cells, indicating activation of the mTOR 292 
pathway by phosphorylation on serine 2448 (56). Higher prolactin and lower leptin levels 293 
have been associated with lymphopenia in severe RSV infection suggesting a neuroendocrine 294 
component although these hormonal differences could also be explained by the systemic 295 
effects of critical illness (57). 296 
 297 
Defective T-cell responses 298 
 299 
Deficits in systemic CD4+ and CD8+ T-cell responses may contribute to RSV susceptibility 300 
in the elderly as these subjects have lower levels of RSV-specific CD4+ and CD8+ T-cells 301 
compared to younger adults (58, 59). Interestingly, there is no decrease in the level of 302 
influenza virus-specific CD8+ T-cells with increasing age (59). Furthermore, 303 
immunosuppressant drugs prescribed for solid organ transplant recipients (glucocorticoids, 304 
calcineurin inhibitors, azathioprine, mycophenolate mofetil, sirolimus) all have inhibitory 305 
activity against T-cells thus impairing the ability of these patients to clear opportunistic RSV 306 
infection, resulting in more severe RSV disease (60). Similarly, haematopoietic stem cell 307 
transplant recipients are also at increased risk of severe RSV disease and peripheral blood 308 
lymphopenia has been identified as a specific risk factor for RSV-LRTI (61) 309 
 310 
Cellular Response in Term and Pre-Term Infants 311 
 312 
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Total cellularity, neutrophil counts, macrophage counts and lymphocyte counts in BAL from 313 
infants ventilated due to RSV-bronchiolitis are all higher in term compared to pre-term 314 
infants, possibly related to immune system maturation (62). 315 
 316 
B-LYMPHOCYTE RESPONSES AND ANTIBODY PRODUCTION DURING RSV 317 
INFECTION 318 
 319 
Antibody Production and B-Lymphocyte Stimulation 320 
 321 
There is an increase in circulating B-cells, including mature (CD19+ CD5+) and precursor 322 
(CD19+ CD10+) cells, in infants with RSV-LRTI and CD20+ B-cells and IgM+, IgG+, and 323 
IgA+ plasma cells are prominent in post-mortem lung tissue from infants with fatal RSV-324 
bronchiolitis (43, 63, 64). Antibody responses target the F and G glycoproteins and increase 325 
between the acute and convalescent phases of natural primary infection of infants (65). 326 
Bronchiolitis may lead to a greater IgG response (66). Type I interferon (IFN) is implicated 327 
in early anti-viral B-cell responses and type I IFN-induced proteins (myxovirus resistance 328 
protein A, 2′,5′-oligoadenylate synthetase 1) are present in high concentrations in bronchiolar 329 
and alveolar epithelial cells from RSV-infected infants (63). The B-cell stimulating factors, a 330 
proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF), are also present, 331 
co-localized to infected epithelial cells. APRIL and BAFF receptors are expressed on a subset 332 
of perialveolar plasma cells. In infants ventilated due to severe RSV-bronchiolitis, pulmonary 333 
BAFF levels are increased (67, 68). BAFF mRNA levels are elevated in bronchial brushings, 334 
further suggesting airway epithelial cells are the source (67). RSV-IgA, -IgG, and -IgM are 335 
present in the lungs of infants with RSV-LRTI together with higher quantities of BAFF and 336 
APRIL, but lower levels of T-cell-dependent cytokines (IL-2, IL-4 and IL-10) (63, 69). 337 
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APRIL concentrations correlate positively with RSV-IgA and IgM levels and inversely with 338 
hypoxia. Thus, the pulmonary antibody response to RSV seems to be predominantly driven 339 
by T-cell-independent antibody production via B-cell stimulating factors (APRIL and BAFF), 340 
likely derived from infected pulmonary epithelial cells. In adults with RSV infection, a longer 341 
duration of virus shedding is associated with prolonged presence of circulating RSV-specific 342 
plasma cells, suggesting that persistent antigenic stimulation in the lung drives B-cell 343 
stimulation (70). Similarly, in elderly adults with nosocomial RSV infection, the highest IgG 344 
and IgA responses post-infection are seen in patients with more severe illness, perhaps 345 
correlating with viral load (71). 346 
 347 
In comparison to healthy controls and rotavirus-infected infants, there is a high prevalence of 348 
anti HEp-2 (antinuclear) antibodies in infants with RSV-LRTI (72). Decay of these auto-349 
antibodies was not studied (nor their presence pre-infection) but further investigation of 350 
subsequent development of autoimmune disease seems warranted. 351 
 352 
Protective Effects of RSV-IgG and RSV-IgA 353 
 354 
In experimental infection of healthy adults, higher pre-inoculation nasal RSV-IgA and serum 355 
anti-RSV neutralizing antibody titres are associated with protection from infection and 356 
reduced viral replication (73-77). RSV-specific nasal IgA, serum IgG and serum neutralizing 357 
titres in adults are also all associated with protection against natural RSV re-infection (78, 358 
79). In experimental infections, nasal RSV-IgA appears to confer more protection than serum 359 
neutralizing antibody and the response may be more durable (74, 80). Similarly, in infants 360 
and children with natural infection it is the development of the IgA response that appears to 361 
correlate with recovery (81). During convalescence, circulating RSV-IgG but not -IgA 362 
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producing memory B-cells are present in contrast to natural influenza virus infection, where 363 
influenza-IgA producing memory B-cells are detectable (74). Overall, a possible deficit in 364 
IgA memory especially in children, when IgA appears to offer important protective 365 
immunity, may contribute to recurrent infections (74, 81). In contrast, in elderly patients it is 366 
a deficit in circulating serum neutralizing antibodies that appears to predispose to RSV 367 
disease (79). 368 
 369 
In symptomatic RSV-infected and non-infected children, circulating RSV-IgG is present at 370 
the highest level in those <1 month old, likely derived from trans-placental maternal antibody 371 
transfer (82). IgG levels decrease after three months until two years, when levels increase 372 
again. The avidity of IgG is significantly lower amongst symptomatic RSV infected infants 373 
aged 1-3 months than in age-matched controls. Similarly, in children aged ≥24 months, total 374 
IgG affinity was lower for children with RSV-LRTI compared to milder URTI. Serum RSV-375 
IgG and nasal RSV-IgA neutralizing activity is quantitatively higher in children aged 9-21 376 
months compared to those aged 4-8 months (the age group with a higher incidence of RSV 377 
infection) (83). In infants there is a reverse correlation between pre-existing serum IgG and 378 
the development of nasal IgA following infection, suggesting maternally derived IgG may 379 
suppress the IgA response (84). These observations suggest that good IgG and IgA avidity for 380 
RSV contributes to protection against both the development of symptomatic infection and 381 
against more serious lung involvement. Following natural re-infection in adulthood, there is 382 
an eightfold increase in serum neutralization titre but this is short-lived, with a fourfold drop 383 
by one year in the majority of cases (85). 384 
 385 
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The serum neutralizing antibody response and nasal IgA and IgG response to the G 386 
glycoprotein are RSV-group specific (86, 87). In contrast, antibodies to the F glycoprotein 387 
are cross-reactive between RSV groups (88). 388 
 389 
Other Mechanisms of RSV-specific Antibody Activity 390 
 391 
Maximal cell-bound C3 is present during the convalescent phase and is associated with cell-392 
bound IgG and IgM (89). RSV antigen containing immune complexes are detectable in the 393 
upper airways of infected infants from three days after the onset of illness, and detectable up 394 
to 36 days after (90). The appearance of such immune complexes coincides with the failure to 395 
detect RSV antigen in airway epithelial cells, possibly due to antibody-dependent cell-396 
mediated cytotoxicity (ADCC), which occurs in infants with primary RSV infection (91). 397 
ADCC activity correlates with the titre of RSV-IgG in the upper airways and is greater during 398 
re-infection than primary infection. 399 
 400 
Immunoglobulin E 401 
 402 
An IgE response is mounted against the RSV F and G glycoproteins and may play a 403 
deleterious role (92). In infants with RSV-bronchiolitis there is a higher proportion of 404 
circulating CD23+ B-cells (CD23 is the low-affinity IgE receptor on mature and activated B-405 
cells) than in non-RSV-bronchiolitis and non-infected infants (93). Nasopharyngeal RSV-406 
IgE, histamine and leukotriene C4 levels are inter-related and associated with bronchiolitis 407 
(where peak levels correlate with hypoxia), compared to other manifestations of infection 408 
(URTI or pneumonia) (36, 94). In children with RSV-bronchiolitis or pneumonia, higher 409 
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serum IgE at admission has been associated with prolonged fever and worse symptoms and 410 
IgE titres and eosinophil counts with the development of wheeze during RSV-LRTI (95-97). 411 
 412 
Th1 AND Th2 RESPONSES TO RSV INFECTION 413 
 414 
Th1 Responses 415 
 416 
Th1 responses are characterised by production of IFN-γ, IL-1, IL-2, IL-12, IL-18, TNF-α. IL-417 
12 induces IFN-γ production and favours Th1 cell differentiation. The Th1 response is pro-418 
inflammatory and important in the generation of cell-mediated immunity required for the 419 
control of intracellular pathogens. Therefore, it is an inherently appropriate response to viral 420 
infection.  421 
 422 
Systemic 423 
 424 
Markers of the Th1 response (IFN-γ, soluble tumor necrosis factor receptor II, soluble 425 
interleukin-2 receptor [sCD25]) are elevated in the circulation during RSV-LRTI and 426 
systemic IFN-γ exerts a protective effect (97-100). Children ≤6 months with RSV-427 
bronchiolitis have a reduced IFN-γ response, possibly contributing to the increased incidence 428 
of RSV disease in the younger age group (101). In infants with RSV-LRTI, systemic IFN-γ 429 
concentrations are lower in those with severe disease (48, 98). Infants with RSV-bronchiolitis 430 
requiring ventilation have lower IFN-γ concentrations compared to those with milder disease 431 
and undetectable circulating IFN-γ positively correlates with the need for ventilation (102). 432 
Low IFN-γ:IL-10 ratios are associated with hypoxia and wheeze (99). During the acute phase 433 
of RSV-LRTI, peripheral blood mononuclear cell IFN-γ mRNA expression is lower in 434 
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hypoxic patients(47). Furthermore, circulating IL-12 levels are lower in severe RSV-LRTI 435 
compared to mild infections or controls (48, 98). 436 
 437 
Respiratory tract 438 
 439 
IFN-γ levels are also elevated in the nasal mucosa (37, 103-106) and in the lung (20, 106). 440 
The respiratory tract IFN-γ response exerts a protective effect, with lower IFN-γ production 441 
associated with increased severity scores, hypoxia and need for ventilation (106-110). In 442 
RSV-LRTI, the nasopharyngeal IFN-γ:IL-10 ratio increases from presentation to discharge, 443 
in parallel with clinical recovery, strengthening the association of IFN-γ with protection (41). 444 
 445 
Other Th1-associated cytokines are also elevated in the nasal mucosa (IL-1, IL-2, IL-12, IL-446 
18, TNF-α) (37, 111, 112) and in the lungs (IL-1, IL-2, TNF-α) (20, 113). TNF-α levels are 447 
highest during the acute phase of infection then decline during recovery (37, 105, 113-115). 448 
Raised IL-6 mRNA and protein have been observed in BAL and nasopharyngeal fluid from 449 
infants with severe RSV infection and a high ratio of IL-6:TNF-α is associated with reduced 450 
disease severity (113, 116). In children with only URTI there is reduced nasal production of 451 
anti-inflammatory IL-10 and this is inversely related to TNF-α production (117). It has been 452 
suggested that a reduction in IL-10 production facilitates a robust TNF-α response, limiting 453 
the infection to the upper airway.  454 
 455 
Increased nasal concentrations of IL-1α are associated with the need for ventilation in 456 
children with RSV-LRTI (118, 119). There is also an increase in nasal IL-18 concentrations 457 
and the number of IL-18 positive cells in children with RSV-bronchiolitis compared to URTI 458 
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(117). In bronchiolitis, nasal IL-18 production is associated with non-hypoxic infection, 459 
consistent with its role in stimulating IFN-γ production (117, 120). 460 
 461 
Th2 Responses 462 
 463 
The Th2 response, characterised by IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 production, is 464 
involved in the generation of antibody (in particular IgE) and eosinophil responses. This 465 
response is associated with atopy and also protection against parasitic infections, and may 466 
counteract and limit Th1-mediated inflammation.  467 
 468 
Systemic 469 
 470 
Systemic IL-4, IL-6, IL-10 and IL-13 levels are elevated in children with RSV-LRTI (37, 97, 471 
101, 121-123). Systemic IL-6 and IL-10 levels correlate with disease severity in RSV-LRTI 472 
including the requirement of supplemental oxygen (99, 122, 124, 125). In comparison to 473 
influenza A virus infection, the systemic concentrations of IL-4, IL-5 and CCL-5 are higher 474 
during RSV-LRTI (126). 475 
 476 
Respiratory tract 477 
 478 
Elevated concentrations of IL-4, IL-6, IL-9, IL-10 and IL-13 have been found in nasal washes 479 
(37, 109, 127-130) and in the lung (20, 131-133) in children with RSV-LRTI. Respiratory 480 
tract IL-10 production appears to exert a protective effect in RSV-LRTI, with concentrations 481 
inversely correlating with the duration of required supplemental oxygen and symptom 482 
severity (108, 128, 132). In very young infants (<3 months) this effect appears to be reversed, 483 
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with IL-10 concentrations correlating with severity (125), and nasal IL-10:CCL-5 ratios are 484 
only inversely correlated with duration of mechanical ventilation when infants older than 5 485 
months are considered (134). 486 
 487 
IL-6 levels are strongly elevated in BAL from infants ventilated due to severe RSV-488 
bronchiolitis (20, 113) and are elevated to a lesser extent in the respiratory tract in infants 489 
with milder infection (37, 117, 132). There are inconsistent data associating the nasal IL-6 490 
response with severity. In infants with RSV-bronchiolitis, nasal IL-6 concentrations are 491 
higher in those requiring ventilation and correlate with the degree of hypoxia (111, 118, 135, 492 
136). Similarly, adults hospitalised due to RSV infection have higher nasal IL-6 493 
concentrations than those not requiring hospitalisation (137). In experimentally infected 494 
adults, nasal IL-6 concentration is positively correlated with viral load and symptom severity 495 
(138). In contrast, in a cohort of children with RSV-bronchiolitis, higher nasal IL-6 496 
concentrations are associated with a shorter requirement for supplemental oxygen (108).  497 
 498 
Th1/Th2 Balance 499 
 500 
A high nasal and systemic IL-4:IFN-γ ratio, a marker of Th2-bias, is associated with severe 501 
(hypoxic) RSV-bronchiolitis (103, 123, 139). Independent of the ratio, IFN-γ concentrations 502 
are lower and IL-4 concentrations higher in infants with severe bronchiolitis. Also in severe 503 
RSV-bronchiolitis, circulating CXCR3+ T-cell (Th1) counts are significantly reduced during 504 
acute infection compared to convalescence, but CCR4+ T-cells (Th2) are not (140). An 505 
excessive Th2 or deficient Th1 response may be associated with the development of 506 
bronchiolitis compared to milder URTI with RSV: the nasal IL-4:IFN-γ and IL-10:IL-12 ratio 507 
is higher in infants with bronchiolitis (141). In a cohort of children with hypoxic RSV-LRTI, 508 
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comparison of systemic and respiratory tract cytokines showed a predominance of Th2 509 
cytokines in nasopharyngeal fluid (higher pulmonary:systemic ratios of IL-4:IL-12, IL-10:IL-510 
2, IL-10:IFN-γ, IL-6:IFN-γ, IL-6:IL-2) (37). Overall, these data suggest a Th2-biased 511 
response may be associated with more severe manifestations of RSV infection, consistent 512 
with it being either an inappropriate response to acute viral infection or one that is required to 513 
limit a potentially detrimental Th-1 response in severe RSV infection. 514 
 515 
However, such findings are not entirely consistent throughout the literature and there are 516 
reports of elevated IFN-γ:IL-4 ratios in children with more severe manifestations of RSV 517 
infection (bronchiolitis, pneumonia, any LRTI) compared to controls albeit not stratified by 518 
severity of infection within the groups (98, 142, 143). A heterogeneous polarization of 519 
pulmonary Th responses in infants with severe RSV-bronchiolitis has also been described, 520 
with 25% of infants only expressing IFN- γ and 50% only expressing IL-4; although again 521 
overall supporting a Th2-bias in severe disease (144). In comparison to infection with human 522 
metapneumovirus (hMPV), infants with RSV infection have similar nasopharyngeal IFN-γ 523 
levels but higher IL-4 consistent with a Th2-biased response that is distinct from the response 524 
to hMPV (34).  525 
 526 
There are lower counts of in vivo RSV-specific T-cells in the elderly and in in vitro 527 
experiments both isolated T-cells and peripheral blood mononuclear cells from healthy 528 
elderly patients produce less IFN-γ when stimulated with RSV F protein or RSV respectively 529 
(58, 59, 145). Although this finding has not been confirmed by in vivo experiments, it does 530 
hint at a defective Th1 response in the elderly which may contribute to the higher incidence 531 
of severe RSV disease in this population. 532 
 533 
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CHEMOKINES, CYTOKINES AND OTHER IMMUNE MOLECULES EXPRESSED 534 
DURING RSV INFECTION 535 
 536 
Overview 537 
 538 
A comprehensive list of immune and lung structural proteins involved in the response to RSV 539 
infection is presented in Table 1. Key molecules are discussed here. 540 
 541 
Interleukin-8 542 
 543 
Systemic and respiratory tract production of IL-8, a neutrophil chemoattractant, is increased 544 
during RSV-LRTI and circulating concentrations normalise during convalescence (37, 102, 545 
105, 111, 121, 122, 133, 146-149). Higher circulating and respiratory tract IL-8 levels are 546 
associated with hypoxia and need for ventilation in infants (18, 37, 102, 135, 136, 147). IL-8 547 
production in the nasal mucosa is also higher during LRTI in children caused by RSV 548 
compared to rhinovirus (150). When comparing term and pre-term infants with RSV-LRTI of 549 
similar severity, nasal IL-8 and leucocyte counts are higher in the term infants suggesting a 550 
more vigorous inflammatory response (151). 551 
 552 
Interleukin-17A 553 
 554 
Compared to non-RSV-LRTI, circulating Th17 cell counts and IL-17 levels are higher in 555 
infants with RSV-bronchiolitis (51). In these infants, nasal concentrations of pro-556 
inflammatory IL-17A are higher in patients requiring ventilation (118). When ventilated, 557 
tracheal IL-17A concentrations positively correlate with neutrophil counts (152). In infants 558 
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with mild bronchiolitis, although nasal IL-17A levels are lower initially, they increase during 559 
the convalescent phase, hinting at a dual role for IL-17A: deleterious in the acute phase, 560 
possibly related to neutrophil recruitment, but potentially involved in the resolution of milder 561 
infections (118). 562 
 563 
CC Chemokines 564 
 565 
CCL-5 (RANTES), eotaxin and CCL-3 (MIP-1α) production in the nasal mucosa and lung 566 
(in BAL) is increased during RSV-LRTI and bronchiolitis (32, 37, 38, 129, 132, 133, 143, 567 
149, 153-155). However, nasal and systemic CCL-5 concentrations are lower in patients 568 
requiring ventilation (18, 132) inversely correlating with the duration of ventilation and 569 
required supplemental oxygen. In RSV-LRTI, the duration of required supplemental oxygen 570 
is positively associated with nasal CCL-3 and inversely with CCL-4 (MIP-1β) (107, 108). 571 
CCL-3 and eotaxin concentrations in the nasal mucosa are higher in hypoxic bronchiolitis 572 
compared to URTI or non-hypoxic bronchiolitis (103, 155, 156). Nasal CCL-3 concentrations 573 
are higher in RSV-infected adults who require hospitalisation, compared to those who do not, 574 
and are associated with symptom severity in experimentally infected adults (137, 138). 575 
However, one study of RSV-LRTI found that increased nasal CCL-2 (MCP-1), CCL-3 and 576 
CCL-4 are all positively associated with severity (119).  577 
 578 
Pattern Recognition Receptors (PRR) 579 
 580 
PRRs are involved in innate immune recognition of viral pathogens in order to stimulate 581 
interferon and cytokine responses. In comparison to healthy controls or infants with 582 
rhinovirus or bocavirus infection, in infants with RSV-bronchiolitis there is increased 583 
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pulmonary expression of TLR-7, TLR-8, RIG-1 and MDA-5 (157). RIG-1 mRNA in the 584 
lungs correlated with RSV viral load (157). Furthermore, an individual’s TLR4 genotype 585 
influences the severity of RSV-bronchiolitis and this is significantly influenced by 586 
environmental lipopolysaccharide exposure (139). 587 
 588 
Innate Interferons 589 
 590 
IFN- α is produced systemically and in the respiratory tract in response to RSV infection 591 
(158). Nasopharyngeal IFN-α titres peak on day 1 of illness and remain elevated for ~6 days, 592 
then decrease in parallel with nasopharyngeal RSV antigen levels (158). In peripheral blood, 593 
IFN-α levels peak by day 2. Infants aged less than 3 months produce the lowest levels of 594 
IFN-α in both the nasopharynx and peripheral blood (158). RSV may be a comparatively 595 
weak inducer of type I IFN since nasopharyngeal IFN-α levels are higher in infants with 596 
influenza virus, adenovirus and parainfluenza virus infection (158). 597 
 598 
Type III interferons (IFN-λ) are produced in response to viral infection and have type I IFN-599 
like activities. Their receptor complex is primarily expressed on epithelial cells and IFN-λ 600 
responsiveness is greatest in organs with high epithelial content such as the lungs. There is a 601 
IFN-λ response to RSV-bronchiolitis, with higher nasal levels of IFN-λ 1-3 seen compared to 602 
rhinovirus infection (159, 160). IFN-λ mRNA levels correlate with IFN-stimulated gene 603 
expression (MxA and ISG56) (159). Despite their association with antiviral gene expression, 604 
higher nasal IFN-λ-1 levels are associated with increased disease severity (159).  605 
 606 
Immunostimulatory defective viral genomes (iDVGs) have been detected in the nasal fluid of 607 
around half of RSV-infected children in one study (161). These RSV genomes have large 608 
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deletions rendering them unable to replicate without the presence of helper virus. The 609 
presence of iDVGs correlates with mRNA levels of IFNA4 and the ISGs IFIT1 and RSAD2, 610 
suggesting they are sufficient to stimulate an innate interferon response (161). 611 
 612 
microRNA 613 
 614 
Viral infection (especially with RNA viruses) can subvert cellular microRNA expression 615 
potentially to the benefit of the virus. A distinct microRNA expression profile is detectable in 616 
the nasal mucosa of RSV-infected infants compared to non-infected controls (downregulation 617 
of miR-34b, miR-34c, miR-125b, miR-29c, mir125a, miR-429 and miR-27b; upregulation of 618 
miR-155, miR-31, miR-203a, miR-16 and let-7d) (162). miR-125a and miR-429 are 619 
downregulated in mild but not severe infection; the former has roles in NF-kappa B signaling 620 
and macrophage function (162). miR-26b (thought to target TLR4 based on miRNA target 621 
prediction software) has been studied in PBMCs from children with RSV-bronchiolitis where 622 
it is up-regulated, negatively correlating with TLR4 expression (163). 623 
 624 
GLOBAL HOST TRANSCRIPTIONAL RESPONSE TO RSV INFECTION 625 
 626 
Genes and pathways associated with neutrophil function, interferon signalling (including 627 
STAT1, STAT2, IFITM1, OAS2, MX1, IFI27, IFI35 and IFIT3), interferon-inducible proteins 628 
(including IFI44, EIF2AK2, IFI44L, IFI6, OAS3 and G1P2), dendritic cell maturation and 629 
inflammation are up-regulated in the circulation of children with RSV infection (164-166). 630 
Genes and pathways associated with NK cell, B-cell and T-cell responses, cytotoxic 631 
lymphocyte-mediated apoptosis of target cells, HLA class I and II and antigen presentation 632 
are under-expressed (164-166). Under-expression is greater in infants <6 months compared to 633 
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those aged 6-24 months (164) and may reflect either low gene expression or migration of 634 
peripheral blood immune cells to the infected tissues. In severe disease there is greater up-635 
regulation of neutrophil and inflammatory gene expression and greater suppression of T-cell, 636 
NK cell and plasma cell associated-genes (164). In comparison, this dysregulation of genes 637 
relating to neutrophil, B-cell and T-cell function is not seen in children with rhinovirus or 638 
influenza virus infection (164). 639 
 640 
A different transcriptional response is seen in the upper airways of RSV-infected children. In 641 
infants requiring supplemental oxygen or mechanical ventilation, ubiquitin D, tetraspanin 642 
8, mucin 13 and β-microseminoprotein are up-regulated and chemokine ligand 7 is down-643 
regulated compared to milder RSV infection (167). 644 
 645 
RELATIONSHIP BETWEEN MOLECULAR AND CELLULAR IMMUNE 646 
RESPONSES TO RSV AND PATHOPHYSIOLOGY 647 
 648 
Molecular and cellular events during RSV infection are reflected in changes in host 649 
physiology observed during the course of disease (Figure 1). The initial development of 650 
cough, wheezing and tachypnoea, usually peaking on days 4-5, develops in parallel to the 651 
maximal neutrophil response and viral load (10). This is followed by a convalescent period 652 
with a CD8+ T-cell predominant response involved in viral clearance which coincides with 653 
the reduction in the above respiratory symptoms over a period of 2-3 weeks. 654 
 655 
Many of the different cytokines, chemokines and other immune molecules that are involved 656 
in the immune response to RSV infection have been associated with protective or deleterious 657 
effects, as listed in Table 1, depending on the perceived severity of disease in the studied 658 
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patients. This is usually based on the need for ICU admission, endotracheal intubation and 659 
mechanical ventilation, but also on composite scores of clinical parameters including 660 
respiratory rate, oxygen saturations, the need for supplemental oxygen or the need for 661 
hospitalisation. 662 
 663 
We know that pre-existing differences in immune status may modulate molecular and cellular 664 
responses during RSV infection. Younger infants have more pronounced lymphopenia and 665 
reduced IFN- γ responses possibly reflecting the immunological immaturity of early life (42, 666 
101). Term infants seem to have a stronger inflammatory response with higher leucocyte 667 
counts and IL-8 levels compared to preterm infants (151). On the other hand, preterm babies 668 
may have an inadequate antiviral response with reduced pulmonary pDC counts (20). These 669 
observations may provide an explanation for the increased frequency of severe RSV disease 670 
in preterm and younger term born infants. 671 
 672 
Furthermore, early life microbiome changes in the gut and respiratory tract may influence the 673 
host immune responses during RSV disease (168), similar to the distinct patterns of 674 
nasopharyngeal microbiota development that have been reported in young infants with cystic 675 
fibrosis (169). Certainly, associations between the respiratory and gut microbiome, host 676 
transcriptional immune responses, RSV load and clinical status are now evident and require 677 
further detailed investigation (170). 678 
 679 
RSV INFECTION AND SUBSEQUENT RESPIRATORY HEALTH 680 
 681 
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RSV-bronchiolitis during early life has been associated with an increase in susceptibility to 682 
subsequent episodic wheeze, physician diagnosed asthma and decreased FEV1 and FVC 683 
measurements on pulmonary function testing (171). Evidence for a causal relationship comes 684 
from an intervention trial in premature infants (gestational age 33-35 weeks) who received 685 
either palivizumab, a humanized monoclonal anti-RSV IgG used in the prevention of severe 686 
RSV disease, or placebo during RSV season (172). Palivizumab treatment almost halved (-687 
46.4%) the proportion of infants with subsequent recurrent wheeze compared to placebo. 688 
Possible molecular and cellular explanations for such a relationship have been described. 689 
There is little human data on potential immune mechanisms for the long term effects of RSV-690 
bronchiolitis, but levels of the cytokines IL-3 and IL-12p40 during RSV disease have been 691 
found to correlate with subsequent development of recurrent wheeze (133). Furthermore, 692 
elevation of VEGF, G-CSF, and IL-10 persists after the RSV episode, all mediators that have  693 
been related to asthma and post-virus induced wheeze (173). Higher proportions of nasal 694 
pDCs may reflect a heightened antiviral response in the respiratory tract, potentially due to 695 
higher viral load, leading to the development of recurrent wheeze and asthma (174). IL-33, 696 
although not reported to be associated with severity of disease, has also been implicated in a 697 
Th2-biased response to RSV and may relate to RSV-mediated asthma in later life (130). 698 
 699 
KEY DIFFERENCES IN THE IMMUNE RESPONSE TO RSV BETWEEN ANIMAL 700 
MODELS AND HUMANS 701 
 702 
Contemporary data from animal models of RSV infection have been comprehensively 703 
reviewed by Borchers and colleagues recently (175). Although similarities are evident the 704 
critical fact remains that human RSV has no animal reservoir and has evolved to infect 705 
humans as its natural host, not the commonly used rodent models, which require infection 706 
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doses far in excess of those needed for human RSV infection. Neutrophilic inflammation 707 
contributes significantly to pathogenesis in humans (where neutrophils can constitute up to 708 
85% of BAL cell counts) but appears to have a less dominant role in mice (15-20% of cells) 709 
(67). In humans the contribution of Th1 and Th2 immune responses is variable and related to 710 
pathogenesis, whereas in mice there is generally a robust and reliable Th1 (IFN-γ) response 711 
(175). The evidence for an important contribution of eosinophils in humans has been 712 
reviewed earlier, but there is no evidence that these cells have a major role in the 713 
pathogenesis of disease in mice (175, 176). 714 
 715 
CONCLUSION 716 
 717 
By synthesizing the results of a systematic literature review of data exclusively from infected 718 
humans, we propose the following model to describe our current understanding of the 719 
immune response to RSV infection in humans (Figure 2). 720 
 721 
Large quantities of pro-inflammatory cytokines are produced in the respiratory tract, with an 722 
initial strong activated pulmonary and systemic neutrophil response which correlates with 723 
disease severity and is mediated by the neutrophil chemoattractant IL-8. Eosinophil 724 
degranulation occurs in the lungs during RSV-bronchiolitis and there may also be a role for 725 
CCL-5-mediated eosinophil recruitment to the lungs during recovery from RSV-LRTI. 726 
Dendritic cells migrate into the lungs where they are the primary antigen presenting cell. 727 
Circulating cDCs exhibit an activated phenotype, and pulmonary cDC counts correlate with 728 
pro-inflammatory and T-cell derived cytokine concentrations suggesting they contribute to 729 
the inflammatory response in a potentially deleterious manner. Alveolar macrophages have 730 
an immune-regulatory and antigen presenting role. 731 
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 732 
Initially, there is a systemic CD4+ and CD8+ T-cell lymphopenia, without evidence for 733 
pulmonary sequestration of T-cells. There is active T-cell apoptosis, upregulation of the T-734 
cell co-inhibitory molecule PD-1 and mTOR-mediated suppression of memory CD8+ T-cell 735 
differentiation, suggesting T-cell interference is a key viral immune evasion strategy (Figure 736 
1). Following the initial neutrophilic response there is a pulmonary CD8+ T-cell response 737 
coinciding with clearance of RSV from the lungs. CD8+ T-cells are protective, likely 738 
mediating viral clearance and therefore enabling resolution of infection. Humoral immunity 739 
to RSV re-infection is incomplete but RSV-specific circulating IgG and secretory IgA are 740 
protective against infection and possibly modify the severity of infection. T-cell-independent 741 
B-cell antibody production via B-cell stimulating factors (BAFF and APRIL) derived from 742 
airway epithelium seems to play a major role in protective antibody generation. On the other 743 
hand, RSV-IgE production is associated with bronchiolitis, where it may have a deleterious 744 
effect. There is strong evidence that IFN-γ (and related to this, IL-12 and IL-18 which 745 
promote IFN-γ production/Th1 differentiation) has a protective role in RSV infection. In 746 
contrast, a Th2-biased response may be associated with more severe disease manifestations. 747 
Global host transcriptional profiling reveals up-regulation of innate inflammatory (e.g. 748 
neutrophil related) genes and suppression of genes associated with the adaptive immune 749 
response. This is exaggerated in severe disease and is specific to RSV infection. Other 750 
cytokines (particularly IL-17A), chemokines (particularly CCL-5 and CCL-3) and local 751 
innate immune factors (cathelicidins, IFN-λ, G-CSF, sICAM-1) have also been associated 752 
with the course of disease. Elderly patients are at increased risk of severe RSV disease and 753 
this susceptibility may relate to defects in circulating neutralizing antibody titres and RSV-754 
specific CD4+ and CD8+ T-cells. 755 
 756 
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Overall, neutrophilic pulmonary inflammation is incriminated as a damaging process and 757 
protective effects of CD8+ T-cells and IFN-γ production are consistently reported. While 758 
these processes may be important therapeutic targets to modulate the immunopathogenesis of 759 
RSV infection, less well characterised immune processes, especially occurring in the lower 760 
airways and lung, require further investigation. 761 
 762 
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FIGURE LEGENDS 1451 
 1452 
Figure 1: Mechanisms of RSV T-cell interference as a potential immune evasion 1453 
strategy 1454 
  59 
RSV infection is associated with an initial systemic T-cell lymphopenia that is quantitatively 1455 
associated with disease severity. RSV may interfere with T-cell responses by (A) inducing 1456 
apoptosis (CD4+ and CD8+ T-cells), (B) inducing increased expression of the programmed 1457 
cell death 1 (PD-1) protein which is inhibitory to activated T-cells (CD8+ T-cells) and (C) 1458 
promoting activation of the mammalian target of rapamycin (mTOR) pathway, thus 1459 
preventing memory CD8+ T-cell formation. 1460 
 1461 
Figure 2: Summary of the human immune response to RSV and potential novel 1462 
therapeutic targets 1463 
The role of major cell types (neutrophils, dendritic cells, macrophages, CD8+ T-cells and B-1464 
cells) is summarised, in addition to key antibody, cytokine, chemokine and other immune 1465 
molecule responses. Major transcriptional changes (in peripheral blood) of immune-related 1466 
pathways are shown. The deleterious role of neutrophilic inflammation and protective role of 1467 
CD8+ T-cell mediated viral clearance is emphasised. Finally, we highlight areas where novel 1468 
therapeutic interventions could potentially modulate the immune response in favour of the 1469 
host. 1470 
↑ indicates immune cell recruitment to the respiratory tract 1471 
*associated with increased disease severity 1472 
 1473 
 1474 
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 1475 
Table 1: Chemokines, cytokines and other immune molecules involved in the human immune response to RSV 
infection 
Immune 
molecule 
Respiratory tracta 
Systemic Additional comments Refb Nasal 
mucosa Lung 
Th1 cytokines      
IFN-γ + + + Protective  
IL-12 + + + Protective  
IL-1α & IL-1β +  + Deleterious  
IL-2 + + + No association reported with severity  
TNF-α + + + Deleterious  
IL-18 +   Protective  
sCD25   + Deleterious  
      
Th2 cytokines      
IL-4 + + + Deleterious   
IL-6 + + + Variable association with severity: see text  
IL-9 + +  No association reported with severity  
IL-10 + + + Variable association with severity: see text  
IL-13 + + + No association reported with severity  
      
Other 
cytokines     
 
IL-8 + + + Deleterious: neutrophil chemoattractant  
IL-17A + +  Variable association with severity: see text  
IL-33 +   No association reported with severity 130 
      
Chemokines      
CCL-2 (MCP-1) + +  Deleterious  
CCL-3 (MIP-1α) + +  Deleterious  
CCL-4 (MIP-1β) +   Variable association with severity: see text  
CCL-5 
(RANTES) + +  Protective 
 
CXCL-10 (IP-
10) +  + Deleterious 
 
Eotaxin + +  Deleterious  
      
Other      
IFN-λ +   Deleterious despite stimulating ISG expression 159, 160 
IFN-α +  + No association reported with severity 158 
G-CSF +  + Circulating G-CSF levels are higher in infants with RSV-LRTI requiring ventilation 
18, 105 
Soluble ICAM-1 +  + sICAM-1 levels in nasal fluid positively correlate with severity 
40, 
124, 
126 
Substance P + +  Lower concentrations associated with increased severity 106 
MBL   − No association reported with severity 44 
Cathelicidin LL-
37 +   
Protective: in human experimental infection, higher 
constitutive nasal cathelicidin LL-37 is associated with 
reduced development of infection 
177 
Olfactomedin 4   + Greater PBMC Olfactomedin 4 gene expression was associated with need for ventilation in RSV-LRTI 
19 
Surfactant A, B, 
D  − + 
The pulmonary level of surfactant A and measurable 
surfactant activity increases during recovery. 
178-
181 
MMP-9, MMP -
3, PGP  +  
Elevated pulmonary levels in ventilated infants are 
associated with hypoxia and acute lung injury  
182-
184 
KL-6   + Circulating KL-6 is greater in infants with RSV-LRTI requiring ventilation 
185 
sTRAIL  +  No association reported with severity 186 
Key. +: increased production; −: reduced production 
a‘Nasal mucosa’ refers to measurements made in nasal fluid or nasopharyngeal aspirate; ‘Lung’ refers to measurements 
made in bronchoalveolar lavage or tracheal aspirate. 
bReferences are provided for molecules not discussed in detail in the main text. 
Abbreviations used in table. CCL: C-C motif chemokine ligand; CXCL: C-X-C motif chemokine ligand; G-CSF: 
granulocyte colony stimulating factor; ICAM: intercellular adhesion molecule; IFN: interferon; IL: interleukin; IP-10: IFN-γ 
inducible protein-10; ISG: interferon stimulated gene; MBL: mannose binding lectin; MCP-1: monocyte chemoattractant 
protein-1; MIP: macrophage inflammatory protein; MMP: matrix metalloproteinase; PGP: proline-glycine-proline (the 
product of MMP hydrolysis of collagen); RANTES: regulated on activation, normal T expressed and secreted; sTRAIL: 
soluble TNF-related apoptosis-inducing ligand; TIMP: tissue inhibitor of metalloproteinase; TNF: tumour necrosis factor. 


